Interestingly, for the anti-apoptosis proteins, a genetic alteration of Mcl-1, involving its amplification, is more common in breast cancer development than Bcl-2 and Bcl-xL amplification in clinical breast cancer datasets and is linked to a worse outcome [6,7]. This evidence concerns the gene MCL1 and breast carcinoma.